Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative

Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, Schaefer-Eckart K, Peterlin P, Hicheri Y, Rahme R, Raffoux E, Chermat F, Krause S, Aulitzky WE, Rigaudeau S, Noppeney R, Berthon C, Goerner M, Jost E, Carassou P, Keller U, Orvain C, Braun T, Saillard C, Arar A, Kunzmann V, Wemeau M, De Wit M, Niemann D, Bonmati C, Schwaenen C, Abraham J, Aljijakli A, Haiat S, Kraemer A, Reichle A, Gnadler M, Willekens C, Spiekermann K, Hiddemann W, Mueller-Tidow C, Thiede C, Roellig C, Serve H, Bornhaeuser M, Baldus CD, Lengfelder E, Fenaux P, Platzbecker U, Ades L (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 106

Pages Range: 3100-3106

Journal Issue: 12

DOI: 10.3324/haematol.2021.278722

Abstract

The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.

Authors with CRIS profile

Involved external institutions

Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Centre Hospitalier Universitaire Amiens-Picardie (CHU Amiens-Picardie) France (FR) Centre hospitalier universitaire de Grenoble France (FR) Technische Universität München (TUM) Germany (DE) Technische Universität Dresden Germany (DE) Hôpital Jean-Minjoz France (FR) Nuremberg Hospital North, North Hospital / Klinikum Nürnberg Nord, Nordklinikum Germany (DE) Robert-Bosch-Krankenhaus Germany (DE) Centre Hospitalier de Versailles France (FR) Hôpital Claude Huriez France (FR) Centre Hospitalier Argenteuil, Hospital Center D'argenteuil France (FR) Hospital Center Sud Francilien / Centre Hospitalier Sud Francilien France (FR) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Regensburg Germany (DE) St. Vincentius-Kliniken / ViDia Kliniken Germany (DE) École Polytechnique - Université Paris-Saclay France (FR) Ludwig-Maximilians-Universität (LMU) Germany (DE) Universitätsklinikum Leipzig Germany (DE) University of Paris 7 - Denis Diderot / Université Paris VII Denis Diderot France (FR) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) France (FR) Hôpital Saint Eloi France (FR) Universitätsklinikum Aachen (UKA) Germany (DE) Centre Hospitalier Universitaire de Nancy / CHU Hôpitaux de Brabois France (FR) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Mannheim Germany (DE) Universitätsklinikum Essen Germany (DE) Klinikum Bielefeld Germany (DE) Le Centre Hospitalier Régional de Metz-Thionville France (FR) Charité - Universitätsmedizin Berlin Germany (DE) Centre hospitalier universitaire (CHU) d'Angers France (FR) University of Paris 13 - Paris-Nord / Université Paris XIII Paris-Nord France (FR) Institute Paoli-Calmettes France (FR) Centre Hospitalier Regional d'Orleans France (FR) Universitätsklinikum Würzburg Germany (DE) Centre Hospitalier de Roubaix France (FR) Vivantes - Netzwerk für Gesundheit GmbH Germany (DE) Gemeinschaftsklinikum Mittelrhein Germany (DE) Ortenau Klinikum Germany (DE) Hospital Center University De Limoges Dupuytren France (FR)

How to cite

APA:

Kayser, S., Schlenk, R.F., Lebon, D., Carre, M., Goetze, K.S., Stoelzel, F.,... Ades, L. (2021). Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative. Haematologica, 106(12), 3100-3106. https://doi.org/10.3324/haematol.2021.278722

MLA:

Kayser, Sabine, et al. "Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative." Haematologica 106.12 (2021): 3100-3106.

BibTeX: Download